| Literature DB >> 15812397 |
Koichiro Yuji1, Shigesaburo Miyakoshi, Daisuke Kato, Yuji Miura, Tomohiro Myojo, Naoko Murashige, Yukiko Kishi, Kazuhiro Kobayashi, Eiji Kusumi, Hiroto Narimatsu, Tamae Hamaki, Tomoko Matsumura, Masahiro Kami, Takahiro Fukuda, Shigeru Masuo, Kazuhiro Masuoka, Atsushi Wake, Junichi Ueyama, Akiko Yoneyama, Ko Miyamoto, Haruhisa Nagoshi, Michio Matsuzaki, Shinichi Morinaga, Yoshitomo Muto, Yoichi Takeue, Shuichi Taniguchi.
Abstract
We report the results of reduced-intensity unrelated cord blood transplantation (RI-UCBT) in patients with advanced malignant lymphoma. Twenty patients (median age, 46.5 years; range, 27-66 years) underwent RI-UCBT with a preparative regimen consisting of fludarabine 125 mg/m2 , melphalan 80 mg/m 2 , and 4 Gy of total body irradiation. The median infused total cell dose was 2.75 x 10(7)/kg (range, 2.3-3.4 x 10(7)/kg). Graft-versus-host disease (GVHD) prophylaxis was composed of cyclosporine or tacrolimus alone. Fifteen patients achieved primary neutrophil engraftment after a median of 20 days. Eight patients developed grade II to IV acute GVHD, and 2 developed chronic GVHD. Of the 16 patients with evaluable disease, 10 achieved a complete response. Primary disease recurred in 1 patient, and transplant-related mortality within 100 days occurred in 8 of 20 patients. The estimated 1-year probability of progression-free survival was 50%. These data suggest that RI-UCBT is a feasible option for patients with refractory lymphoma who lack an HLA-matched donor.Entities:
Mesh：
Year: 2005 PMID： 15812397 DOI： 10.1016/j.bbmt.2005.01.012
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN： 1083-8791 Impact factor: 5.742